Win More Projects, Reduce Delays, and Optimise Your Trial Strategy

Optimised trial protocols that increase RFP win rates.

CROs can now leverage cutting-edge AI technology to win more projects, optimise trial strategies, and reduce delays. TrialKey’s Preliminary Report offers data-driven insights to elevate your RFPs and refine trial designs—all at no cost.

Request a demo

Request a Sample Report

Key Advantages Of The Preliminary Report

Present a compelling case to sponsors with our AI-backed preliminary report. Designed to support your RFP, this 4+ page report provides:
 

What’s Included:

  • Success Probability Score
    Results from 100,000 simulations provide a robust success forecast for your trial.
  • Competitive Benchmarking
    See how your trial stacks up against competitors, including success rates and benchmarks.
  • Technology Landscape Insights
    Discover key technologies and their impact on similar trials in your therapeutic area.
  • Sponsor Analysis
    Identify organisations with a history of success in your space and their trial outcomes.

Designed for CRO Success

Our free report equips CROs with actionable insights to strengthen proposals, refine strategies, and attract sponsors. Backed by 30+ years of global trial data, you’ll gain the tools needed to outpace competitors and win critical projects.

 

Disclaimer: Preliminary Reports are available only for pharmaceutical and contract research organisations. The content is not available to funds or other entities.

This information is not financial advice. No warranties are given about accuracy or completeness. Use of this site is at your own risk. Liability for use outside these parameters is disclaimed.

Trusted by

:
:
:
:
:
:
:
:

Transparent Process for Reliable Outcomes

  • Protocol Review & Analysis
    Upon receiving your trial protocol or synopsis, our AI models pull relevant data from global registries, generating initial recommendations based on proven success factors.

  • Preliminary Report for RFP Success
    Within five business days, receive a success probability score, competitor insights, and data visuals to strengthen your proposal.

  • Comprehensive Data Collection
    Once the project is secured, we perform a full analysis of both structured and unstructured data, ensuring all critical insights are considered.

  • Detailed Full Report for Execution
    TrialKey delivers a comprehensive roadmap, covering site selection, recruitment, protocol optimisation, and competitor analysis to ensure a streamlined execution.

Benefits of TrialKey’s Compensation Model for CROs

  • Risk-Free Initial Engagement
    TrialKey’s free preliminary report gives CROs the confidence to evaluate the potential and precision of our advanced AI-powered tools before committing.
  • Transparent Pricing
    The fixed fee structure eliminates uncertainty, enabling CROs to budget effectively without hidden charges or unexpected expenses.
  • Streamlined Process
    Our invoicing and payment terms are designed for simplicity and efficiency, allowing CROs to focus on trial success rather than administrative burdens.
  • Adaptability for Decision-Making
    The non-funding clause empowers clients to explore TrialKey’s capabilities with no financial pressure, ensuring decisions are well-informed and data-driven.

Request an Expert Consultation

TrialKey is more than a feasibility tool – it’s a competitive advantage.

Our AI-powered biostatistical tools provide tailored insights, helping you validate your research question, determine sample sizes, and optimise study protocols for clarity, feasibility, and reliability.

Join the CROs transforming clinical trials with TrialKey.

We are excited to collaborate with Opyl and leverage their advanced AI capabilities to enhance the innovative data driven insights we provide to our clients. This partnership also aligns with our global AI strategy to co-create innovative AI enabled solutions with our own dedicated best in class expertise and tools and the right partners. The insights gained through Opyl's platform will enhance our ability to guide our clients through complex market landscapes and position them for success and most importantly, to enable better and faster access for patients to life saving and life changing therapies”
Tanya van der Wall
Tanya van der WallCountry Managing Director at Commercial Eyes
“Working with TrialKey has been transformative for Brain Vector. The insights from their comprehensive report have significantly reduced costs and time while providing invaluable data that sharpened our focus on the most impactful areas. This collaboration has laid a strong foundation for our clinical trial and our broader mission to enhance mental health care.”
Dr. Stephane Verhaeghe
Dr. Stephane Verhaeghe CEO of Brain Vector
"Our collaboration with Opyl enables us to offer suppliers the cutting-edge tools needed to navigate the complex regulatory environment in Australia. TrialKey’s data-driven validation reports are an essential resource for any supplier looking to build credibility and trust within the healthcare community."
Gillian Alexis
Gillian AlexisCEO of Phenix Health
"We are excited to collaborate with Opyl and leverage TrialKey's advanced AI-driven trial design capabilities. This partnership aligns with our commitment to delivering high-quality, data-backed clinical trial projects to our clients. By incorporating TrialKey's insights into our projects, we are confident in our ability to deliver more efficient and effective clinical trials.” 
Tina Soulis
Tina SoulisFounder and Director at Alithia Life Sciences
"Integrating Opyl’s TrialKey platform into our clinical trial design services brings significant value to our clients. With over 30 years in the pharmaceutical and biotech industry, I see the critical role that data-driven insights play in optimising trial outcomes. TrialKey’s capability to analyse large datasets and provide reliable biostatistical validation is exactly what our clients need to drive product development forward." 
Jacqui Wade
Jacqui WadeDirector, Clinical Affairs & Director Services at Biointelect
“At Southern CDC, we are committed to advancing drug development and enhancing patient treatment through our tailored solutions. TrialKey’s advanced analytics, unlocks new opportunities to refine trial designs, optimise site selections, and develop recruitment strategies that truly meet patient needs. This partnership empowers us to accelerate clinical trials for our sponsors, effectively addressing unmet medical needs with agility and precision. We’re excited to jointly expedite the development of life-changing treatments, where every day counts.”
Dr Khalid Abubaker
Dr Khalid Abubaker Chief Operating Officer of Southern CDC:
"The preliminary report was a revelation—TrialKey delivered insights that were both precise and transformative. We’re thrilled to expand this collaboration as we work to bring our therapies to patients faster and more efficiently. TrialKey empowers us to innovate with confidence, refining our trial strategies and addressing critical unmet needs in neurological care.”
Dr Steven Petratos
Dr Steven PetratosChief Scientific Officer of NeuOrphan
Book a Demo